PHILADELPHIA, March 17, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Alternext US:HEB) has scheduled a conference call and audio webcast to discuss its year-end 2008 results and the new clinical data recently presented at the 9th International IACFS/ME conference held in Reno, NV from March 12 - 15, 2009. The conference call and webcast are scheduled for Thursday, March 19, 2009 at 10:00 AM EDT.
At the 9th International IACFS/ME conference, Dr. David Strayer, Hemispherx's Medical Director, presented new, never before released cytokine data and cardiovascular data which has been included in the New Drug Application (NDA) filed with the Food and Drug Administration (FDA) with a current PDFUDA date of May 25, 2009. Dr. William Carter, Hemispherx's Chairman and CEO, will discuss the data and its significance on the conference call. The presentation given by Dr. Strayer at the conference is available for review one hour prior to this conference call on the company's website at www.hemispherx.net.
To access the conference call: U.S. Callers: 800-346-7359 International Callers: 973-528-0008 Conference Entry Code: 520147
This call will be webcast via the Company's website at: http://www.hemispherx.net.
A digital replay of the call will be available until April 2, 2009 by calling: U.S. Callers: 800-332-6854 International Callers: 973-528-0005 Conference Entry Code: 520147
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon(r) LDO and Oragens(r)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications; Similarly, the completion of NDA filing process with Ampligen(r) does not imply that the product will ever be approved commercially.